Combined modality radioimmunotherapy for hormone refractory metastatic prostate cancer with two cycles of escalating dose 90Y-DOTA-peptide-m170 [anti-MUC1 monoclonal antibody m170-Y-90] and fixed, low dose paclitaxel with blood stem cell support and cyclosporin [ciclosporin] for HAMA [human anti-mouse antibody] suppression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-MUC1 monoclonal antibody m170-Y-90; Ciclosporin; Paclitaxel
- Indications Prostate cancer
- Focus Adverse reactions
- 20 Sep 2013 Biomarkers information updated
- 30 Sep 2005 New trial record.